SciClone Pharmaceuticals said Monday that a second round of testing showed again that patients who used its vaccine booster combined with a swine flu vaccine had better resistance levels.
In January, SciClone first reported tests using its Zadaxin booster and Novartis AG's vaccine Focetria.
SciClone and its partner Sigma-Tau said an immune response was achieved in 93 percent of patients who received a low dose of Zadaxin and 94 percent of patients who received a bigger dose. That compares to 77 percent of patients who received only Focetria.
SciClone Pharmaceuticals Inc. said it will report more data from the study in about six months.